Fate Therapeutics
FATE
$4.00
Share price
5.39%
Change (1 day)
-34.02%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Cash on Hand
Cash on Hand as of December 2023 : $0.31 B
According to Fate Therapeutics
's latest financial reports the company has $0.31 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Fate Therapeutics - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.31 B | -27.75% |
| 2022-12-31 | $0.43 B | -29.17% |
| 2021-12-31 | $0.61 B | 27.54% |
| 2020-12-31 | $0.48 B | 118.09% |
| 2019-12-31 | $0.22 B | 10.16% |
| 2018-12-31 | $0.20 B | 99.12% |
| 2017-12-31 | $0.10 B | 9.59% |
| 2016-12-31 | $92.11 M | 42.13% |
| 2015-12-31 | $64.8 M | 31.99% |
| 2014-12-31 | $49.1 M | -9.13% |
| 2013-12-31 | $54.03 M | 494.65% |
| 2012-12-31 | $9.08 M | 42.27% |
| 2011-12-31 | $6.38 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | $1.18 B | 275.03% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $1.67 B | 431.85% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $0.87 B | 178.18% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.03 B | 227.31% | 🇺🇸 USA |
 Avidity Biosciences RNA | $0.59 B | 88.90% | 🇺🇸 USA |